Survival After Chemotherapy for Gastric Cancer
Author Information
Author(s): Waters J S, Norman A, Cunningham D, Scarffe J H, Webb A, Harper P, Joffe J K, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T
Primary Institution: Cancer Research Campaign (CRC) Section of Medicine and Gastrointestinal Unit, Royal Marsden Hospital and Institute of Cancer Research
Hypothesis
Does the ECF regimen provide better survival outcomes compared to the FAMTX regimen in patients with advanced oesophagogastric cancer?
Conclusion
The ECF regimen leads to better response and survival rates compared to the FAMTX regimen in patients with advanced oesophagogastric cancer.
Supporting Evidence
- The overall response rate was 46% with ECF and 21% with FAMTX.
- The median survival was 8.7 months with ECF and 6.1 months with FAMTX.
- The 2-year survival rates were 14% for the ECF arm and 5% for the FAMTX arm.
- Histologically complete surgical resection was achieved in ten patients in the ECF arm.
Takeaway
Doctors tested two types of chemotherapy for stomach cancer, and one worked much better than the other, helping more people live longer.
Methodology
A randomized study comparing ECF and FAMTX regimens in previously untreated patients with advanced oesophagogastric cancer.
Participant Demographics
Patients with adenocarcinoma or undifferentiated carcinoma, previously untreated.
Statistical Information
P-Value
0.00003
Confidence Interval
95% CI, 37–55%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website